Navigation Links
The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research
Date:7/6/2009

WHITE PLAINS, N.Y., July 6 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) and The International Waldenstrom's Macroglobulinemia Foundation (IWMF) have partnered in an initiative to develop stable and immortalized Waldenstrom's macroglobulinemia (WM) cell lines that would be made widely available to researchers to test potential new treatments for the disease.

WM occurs as low-grade B-cell non-Hodgkin lymphoma, characterized by B-lymphocytes in the bone marrow, and an abnormal level of the protein monoclonal immunoglobulin M (IgM). Though the disease is slow-growing, a curative treatment has yet to be developed. Cell lines are invaluable in understanding the genetics and biology of cancerous cells. The development of a biologically stable and satisfactorily representative WM cell line will enable researchers throughout the world to test their latest ideas on bio-identical cells and thus compare their results with those of other researchers.

Researchers agree that new cell lines are urgently needed as it is widely understood that the three most used existing WM cell lines may not accurately represent the disease.

"Numerous scientists studying WM report that one of the barriers to finding a cure is the lack of a standardized WM cell line," said LLS Chief Scientific Officer Louis J. DeGennaro, Ph.D. "Together, LLS and IWMF are committed to seeing this critical asset developed in a way so as not to fundamentally change the cellular and functional characteristics of the original tumor, and thus enable researchers to better understand the unique aspects of WM biology and advance more effective treatments for WM patients."

Under the agreement, LLS and IWMF will seek applications and select up to three laboratories to co-fund for up to $100,000 for one year. Continued funding, potentially for up to two additional years, will be contingent on available funds and assessments of progress toward the goal of developing suitable cell lines.

"IWMF has funded several research projects where WM cell lines have been utilized," said Tom Meyers, Ph.D., IWMF vice president of research. "In most cases it is difficult to compare some of the research results because the cell lines are different. This will no longer be the case if this cell line development is successful."

To read about the request for applications or to fill out an application, please visit the following links:

http://www.leukemia-lymphoma.org/graphics/National/Web/WaldenstromsMacroglobulinemiaRFAInformationPacket.pdf

http://www.leukemia-lymphoma.org/graphics/National/Web/WM_LLS_Application_Template.doc

About The Leukemia & Lymphoma Society

The Leukemia & Lymphoma Society(R) (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org or contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 6 p.m. ET. www.lls.org.

About The International Waldenstrom's Macroglobulinemia Foundation

The IWMF was started in 1994 when Arnold Smokler, a pharmacist, developed the disease and could find little information about it. Initially, he formed a support group in the Washington, D.C. area. By 1998 the organization had grown substantially and it was incorporated in Florida as a non-profit corporation under its current name. The organization has continued to grow with worldwide membership of nearly 4,000. The IWMF provides support to patients and their caregivers, enables patients and caregivers to communicate with one another, sponsors educational forums on the disease featuring prominent doctors and researchers associated with the disease, publishes booklets on the disease and its treatment and supports research aimed at understanding the disease and, ultimately finding a cure. Since 2000, nearly $4 million has been given to institutions conducting research on the disease.

    Contact: Andrea Greif, (914) 821-8958
    andrea.greif@lls.org


'/>"/>
SOURCE The Leukemia & Lymphoma Society
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
2. Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma
3. Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting
4. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
5. International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"
6. In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia
7. Alfacells ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells
8. Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias
9. Not the protein, but its location in the cell, determines the onset of leukemia
10. Lorus Therapeutics Announces Publication of a Clinical Study Demonstrating Encouraging Results with LOR-2040 in Combination with Cytarabine in Patients with Acute Myeloid Leukemia (AML)
11. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... 2016  Regular discussions on a range of subjects including ... two entities said Poloz. Speaking at a lecture ... , he pointed to the country,s inflation target, which is ... "In certain areas there ... common economic goals, why not sit down and address strategy ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016 The Department of Transport Management ... 44 million US Dollar project, for the , ... Personalization, Enrolment, and IT Infrastructure , to ... and implementation of Identity Management Solutions. Numerous renowned international vendors ... Decatur was selected for the most compliant and ...
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:4/28/2016)... and BANGALORE, India , April 28, 2016 ... a product subsidiary of Infosys (NYSE: INFY ), ... a global partnership that will provide end customers ... mobile banking and payment services.      (Logo: ... innovation area for financial services, but it also plays a ...
Breaking Biology News(10 mins):